Portable CRISPR-Based Molecular Technology Brings Highly Accurate Diagnostics to Point of Need

A comprehensive solution for point-of-care diagnostics harnesses the power of CRISPR-Cas for extreme accuracy in an onsite setting.

Scope Biosciences B.V.’s (Wageningen, Netherlands) scopeDx is a next-gen CRISPR-based molecular diagnostics platform that delivers ultra-precise, single-nucleotide detection in a format that is portable and field-ready without proprietary hardware or centralized labs. The scopeDx platform uses proprietary type III CRISPR-Cas technology to detect nucleic acid sequences, dramatically enhancing the ability to detect genetic material with ease, speed and accuracy, for use in molecular diagnostics in infectious diseases, genotyping, and other applications. scopeDx combines isothermal LAMP amplification with a novel type III CRISPR-Cas technology to detect target nucleic acid material. This brings together rapid isothermal amplification characteristics with extreme specificity due to the CRISPR-Cas module, and leads to a high-performing diagnostic solution.

Image: scopeDx uses proprietary type III CRISPR-Cas technology to enable rapid diagnostics at POC (Photo courtesy of Adobe Stock)

The robust scopeDx workflow includes a quick, hardware-free, sample extraction step with minimal reagent handling steps to improve ease of use & reliability. scopeDx is suitable for the detection of both RNA and DNA, in under 25 minutes, and is sensitive enough to detect the smallest amount of genetic material. It is capable of detecting single-nucleotide variations if desired, while its isothermal nature allows for simple, intuitive, and portable readout with minimal training. Multiple samples (extraction and controls) are amplified and measured in real-time, for specific and fast confirmation of the presence of the pathogen of choice. The scopeDx technology allows diagnostics to be performed closer to the source — in the field, at the point of care and contributes to faster and broader access to reliable testing, especially in areas where centralized laboratories are not available.

Designed to offer an unparalleled "sample to answer" solution, scopeDx ensures rapid, accurate, and accessible diagnostic services in various settings, including hospitals and remote clinics. The versatility of scopeDx stems from its capability to perform highly specific on-site testing, facilitating rapid and efficient diagnostic procedures. This becomes especially pivotal in scenarios requiring immediate results, minimizing the delay between testing and vital treatment initiation. By empowering healthcare settings with accurate and reliable diagnostic tests, scopeDx bridges the gap between immediate healthcare needs and specialized diagnostics.

“We’re scaling up, building out our platform and getting ready to meet real-world diagnostic challenges head-on,” said Niek Savelkoul, CEO and founder of ScopeBio.

Related Links:
Scope Biosciences B.V.